AAPG: Ascentage Pharma Group International Kompaniya qiymatining sof foydaga nisbati

Ascentage Pharma Group International - AAPG emitenti grafik logotipi

Ascentage Pharma Group ning yuqori daromadliligi biomateriallar yetkazib berishni optimallashtirish va ta'minot zanjiri nazoratiga asoslangan. Kompaniyaning P/E koeffitsiyenti haqiqiy daromadlar va bozor kutsivlari o'rtasidagi muvozanatni aniq ko'rsatadi, bunda -3.70 ushbu metrikaning joriy darajasini ifodalaydi. Biroq, global sog'liqni saqlash gigantlarining kengayishi bosim o'tkazmoqda, bu esa kompaniyani omon qolish uchun strategik hamkorlarni izlashga va chidamli o'smalarga qarshi kurashishning innovatsion usullarini ishlab chiqishga majbur qilmoqda.

Narx-foyda koeffitsiyenti: Ascentage Pharma Group (AAPG) 25.01.2025 - 12.11.2026 uchun

Ascentage (AAPG) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- aksiya kursi va ekspertlarning narx prognozi:
Narxlar dinamikasi grafigi ascentage.com|AAPG - Konsensus maqsadli narx
- bozor kapitallashuvi haqida ma'lumot:
Bozor qiymati Ascentage Pharma Group|AAPG - Korxona qiymati
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
Bitta aksiya uchun buxgalteriya qiymati Ascentage Pharma|AAPG - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga nisbati ascentage.com|AAPG - Kompaniyaning jami aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Barcha qarzlarning o‘z mablag‘lariga nisbati Ascentage Pharma Group|AAPG - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Ascentage Pharma Corp|AAPG - Kompaniyaning jamlangan qarzlari|Balans kapitallashuviga qarzlar Ascentage Pharma Group|AAPG - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz hajmi Ascentage Pharma|Tezkor likvidlik ko‘rsatkichi ascentage.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
AAPG - Sof foyda|Kutilayotgan sof foyda Ascentage Pharma Group|AAPG - Narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati Ascentage Pharma Group International|AAPG - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati koeffitsiyenti Ascentage Pharma Group|AAPG - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Ascentage Pharma|AAPG - Bir aksiya uchun sof foyda (EPS TTM)|Sirpanuvchi yil uchun bir aksiya uchun sof foyda o'sishi ascentage.com|AAPG - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi Ascentage Pharma Group
Kompaniyaning jamlanma tahlili:AAPG, ascentage.com
Ascentage Pharma yetakchi tovari

Ascentage Pharma Group (AAPG) tomonidan leykozga qarshi dori vositalari uchun xalqaro sinovlarning kengayishi operatsion pul oqimiga bo'lgan bozor kutuvlarini aks ettirgan holda, joriy narx-foyda koeffitsiyenti dinamikasini harakatga keltirmoqda. Ushbu koeffitsiyent sof foydaning bir birligi uchun xarajatni o'lchaydi, bu esa investorlarga matematik qayta muvozanatlash orqali aktivning qizib ketish darajasini aniqlash va allaqachon narxga kiritilgan R&D xarajatlarini hisobga olgan holda, kapital risklarini o'z vaqtida yumshatish imkonini beradi.

Raqobatdosh kompaniyalar tahlili

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori CGON (CG Oncology Corp)|URGN - Narx-foyda koeffitsiyenti|BCAX: Narx-foyda koeffitsiyenti|PSNL - P/E multiplikatori|Erasca (ERAS) - Narxning foydaga nisbati|Delcath Systems Inc - Kompaniya qiymatining sof foydaga nisbati|YMAB (YmAbs) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aura Corp AURA|P/E multiplikatori CADL|P/E multiplikatori accuray.com (ARAY)|Narxning foydaga nisbati SELLAS Life Sciences Group SLS|Biznesning o‘zini qoplash muddati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - P/E multiplikatori|TuHURA Biosciences, Inc. (HURA) - Narx-foyda koeffitsiyenti|TARA: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati fatetherapeutics.com (FATE)|Narxning foydaga nisbati Aadi Bioscience, Inc.|Narx-foyda multiplikatori TCRX (TScan)|Narx-foyda koeffitsiyenti CSBR (Champions Oncology)|Bozor narxining sof foydaga nisbati XBIT|P/E multiplikatori CVM (CEL-SCI)|P/E multiplikatori ostherapies.com OSTX|Radiopharm Theranostics - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Artiva Biotherapeutics, Inc. (ARTV)|ANL: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Veru Corporation (VERU)|Narx-foyda koeffitsiyenti TPST|XLO: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Renovaro Inc. (RENB)|MURA: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori KAPA (Kairos Pharma)|Kompaniya qiymatining sof foydaga nisbati OKUR|CytoMed - P/E multiplikatori|CRIS - P/E multiplikatori|apollomicsinc.com (APLM) - Narxning foydaga nisbati|Tharimmune Inc - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Advanced Biomed Inc.|Narx-foyda koeffitsiyenti Genprex Inc (GNPX)|P/E multiplikatori CLDI|P/E multiplikatori sunshinebiopharma.com (SBFM)|Xenetic Biosciences, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati SLRX|Purple Biotech Corp - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti American Oncology Network (AONC)|BeiGene, Ltd. (BGNE) - Narxning foydaga nisbati|checkpointtx.com - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Elevation Oncology|Kapitalizatsiyaning foydaga nisbati iCAD Corp ICAD|Narx-foyda koeffitsiyenti IKNA (Ikena Oncology, Inc.)|P/E multiplikatori Notable Labs Corp (NTBL)|Narxning foydaga nisbati Viracta Therapeutics, Inc. VIRX|MOR (morphosys.com) - Kapitalizatsiyaning sof foydaga nisbati|NAYA Biosciences Inc. - P/E multiplikatori|AAPGV - P/E multiplikatori